Back to Results

Eyepoint Pharmaceuticals Inc (EYPT)

EyePoint Pharmaceuticals Inc. is a NASDAQ-listed common stock issuer focused on developing and commercializing therapies for serious retinal diseases. The company’s pipeline is built around its proprietary Durasert E bioerodible platform, which is designed for sustained drug delivery inside the eye. Its lead candidate, DURAVYU, combines vorolanib, a selective tyrosine kinase inhibitor, with Durasert E and is in Phase 3 clinical trials for wet age-related macular degeneration and diabetic macular edema. EyePoint’s development program also includes EYP-2301, a TIE-2 agonist formulated with Durasert E and currently in pre-clinical development. Founded in 2000 and headquartered in Watertown, Massachusetts, the company changed its name from EyePoint Pharmaceuticals, Inc. to EyePoint, Inc. in December 2025.


Stock Summary Fair Value Profitability & Growth Quality & Risk Events & Dividends Market Outlook FAQ

Jump directly to the stock analysis sections supported by the latest available data.

Data update note: Fair value and stock analysis metrics are updated after regular market sessions when new data becomes available.
Ticker Fair Value Fair Value Upside/Downside Fair Value Rating Analyst Price Target Analyst Target Upside/Downside Analyst Target Rating Overall Financial Health Dividend Yield Price-to-Book Ratio Price-to-Sales Ratio Market Cap Enterprise Value Total Debt / Total Capital Free Float / Shares Outstanding Altman Z-Score Free Cash Flow / Net Income
NASDAQ-EYPT
$0.48
35.1% Upside
Undervalued
$8.44 2,270.1% Upside
Not available
Bargain
Weak
0.0%
0.2x
11.0x
30.407 M
-127.4 M
39.6%
70.4%
-17.4
88.5%
Valuation • Fair Value

Eyepoint Pharmaceuticals Inc (NASDAQ-EYPT) Fair Value by Valuation Model

Review the available estimates for Eyepoint Pharmaceuticals Inc (NASDAQ-EYPT), including Comps Fair Value.

Primary Valuation Read

Fair Value

$0.48

Estimated upside of 35.1% versus the current market price.

Fair Value Confidence

Low

Confidence level for the primary fair value estimate.

Comps Fair Value

$0.48

Comparable-company valuation reference.

Analyst Price Target

$8.44 2,270.1% Upside

Current consensus analyst target, where available.

How to read these valuation models

Use the 4 available valuation references for Eyepoint Pharmaceuticals Inc (NASDAQ-EYPT) as analytical inputs, not a standalone conclusion. Valuation methods can differ because they rely on different assumptions, time horizons and financial inputs; compare the estimates with the current price and the company’s financial quality.

Profitability • Growth

Profitability & Growth for Eyepoint Pharmaceuticals Inc (NASDAQ-EYPT)

Review the profitability and growth indicators currently supported by the latest data.

Revenue

2.788 M

Current operating scale indicator.

Revenue Forecast

1.555 M

Forward revenue estimate.

EBITDA

-314.4 M

Current operating profitability reference.

EBITDA Forecast

-380.7 M

Forward operating profitability estimate.

How to read profitability and growth

This section helps investors review Eyepoint Pharmaceuticals Inc (NASDAQ-EYPT) from an operating perspective by combining current scale, forward revenue expectations and EBITDA-related profitability measures.

Quality • Risk

Quality & Financial Risk for Eyepoint Pharmaceuticals Inc (NASDAQ-EYPT)

Review the financial quality and risk indicators currently supported by the latest data.

Financial Health

Weak

Financial pressure deserves closer review.

Piotroski Score

0

Weak quality score that deserves closer review.

Beneish M-Score

-7.05

No elevated caution signal from this screen.

Altman Z-Score

-17.4

Lower score that deserves closer risk review.

FCF / Net Income

88.5%

Cash conversion quality indicator.

How to read quality and risk

This section combines quality, balance-sheet and accounting-risk indicators for Eyepoint Pharmaceuticals Inc (NASDAQ-EYPT). Read the metrics together: no single score is a complete investment conclusion, but the combined view can highlight financial strength, earnings quality and areas that may deserve closer review.

Events • Dividends

Dividend Profile for Eyepoint Pharmaceuticals Inc (NASDAQ-EYPT)

Review the dividend metrics currently supported by the latest data.

Dividend Yield

0.0%

No current dividend yield is indicated.

How to read events and dividends

The latest data indicates no current dividend yield for Eyepoint Pharmaceuticals Inc (NASDAQ-EYPT). No upcoming dividend amount or event date is currently available.

Stock Forecast • Technical Outlook

Eyepoint Pharmaceuticals Inc (NASDAQ-EYPT) Stock Forecast & Technical Outlook

Review Eyepoint Pharmaceuticals Inc (NASDAQ-EYPT) across multiple technical time frames, alongside analyst recommendation data, to form a faster read on market positioning and near-term sentiment.

Technical Signals by Time Frame

Switch between time frames to review the current technical signal for the stock.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: 15-minute • intraday
Strong Sell

The 15-minute technical read for Eyepoint Pharmaceuticals Inc (NASDAQ-EYPT) is currently Strong Sell. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: 1-hour • short-term
Strong Sell

The 1-hour technical read for Eyepoint Pharmaceuticals Inc (NASDAQ-EYPT) is currently Strong Sell. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: daily • daily
Strong Sell

The daily technical read for Eyepoint Pharmaceuticals Inc (NASDAQ-EYPT) is currently Strong Sell. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: weekly • weekly
Strong Sell

The weekly technical read for Eyepoint Pharmaceuticals Inc (NASDAQ-EYPT) is currently Strong Sell. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: monthly • monthly
Strong Sell

The monthly technical read for Eyepoint Pharmaceuticals Inc (NASDAQ-EYPT) is currently Strong Sell. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

Analyst Consensus for Eyepoint Pharmaceuticals Inc (NASDAQ-EYPT)

A consolidated view of buy, hold and sell recommendations based on the currently available analyst data.

Strong Sell Sell Neutral Buy Strong Buy
Consolidated analyst recommendation mix
Hold

Based on the available recommendation mix, Eyepoint Pharmaceuticals Inc (NASDAQ-EYPT) has a Hold consensus, with 2 buy, 10 hold and 0 sell recommendations in the current data set.

Buy 2
Hold 10
Sell 0
FAQ • Fast Investor Answers

Eyepoint Pharmaceuticals Inc (NASDAQ-EYPT) Stock FAQ

Data-supported answers about Eyepoint Pharmaceuticals Inc (NASDAQ-EYPT), including explicit coverage status where a reliable valuation estimate is not currently available.

Fair Value
$0.48
Estimated upside 35.1%
Valuation Rating
Undervalued
Estimated upside of 35.1%
Analyst Target
$8.44 2,270.1% Upside
Data is currently unavailable
Financial Health
Weak
Current financial-health read

The current fair value estimate for Eyepoint Pharmaceuticals Inc (NASDAQ-EYPT) is $0.48. This implies an estimated upside of 35.1% versus the current market price.

Based on the current fair value estimate, the stock appears undervalued, with estimated upside of 35.1% versus the current market price.

The available analyst price target for Eyepoint Pharmaceuticals Inc (NASDAQ-EYPT) is $8.44 2,270.1% Upside.

The current financial health read for Eyepoint Pharmaceuticals Inc (NASDAQ-EYPT) is Weak. This should be reviewed alongside valuation, profitability, debt and cash-flow quality metrics.

The latest available data indicates no current dividend yield for Eyepoint Pharmaceuticals Inc (NASDAQ-EYPT).

The current market capitalization listed for Eyepoint Pharmaceuticals Inc is 30.407 M.

The current enterprise value listed for Eyepoint Pharmaceuticals Inc is -127.4 M. Enterprise value can provide a broader valuation view than market capitalization alone because it also considers net debt.

The ticker symbol for Eyepoint Pharmaceuticals Inc is NASDAQ-EYPT, and the stock is listed on NASDAQ.

Eyepoint Pharmaceuticals Inc (NASDAQ-EYPT) is listed on NASDAQ.

The current debt-to-total-capital ratio listed for Eyepoint Pharmaceuticals Inc is 39.6%, which helps investors evaluate the company’s financing structure and leverage profile.

The free float listed for Eyepoint Pharmaceuticals Inc is 70.4%. Free float helps investors understand how much of the share base is available for public trading.

Similar Pharmaceuticals Stocks View more on NASDAQ

Comparable companies from the same industry, limited to one security per issuer.

LLY NYSE Eli Lilly and Company Fair Value Fair Market Cap 1,215.6 B
JNJ NYSE Johnson & Johnson Fair Value Fair Market Cap 655.6 B
MRK NYSE Merck & Company Inc Fair Value Fair Market Cap 362.2 B
NVS NYSE Novartis AG ADR Fair Value Fair Market Cap 310 B
NVO NYSE Novo Nordisk A/S Fair Value Bargain Market Cap 179.5 B
PFE NYSE Pfizer Inc Fair Value Fair Market Cap 170.3 B
BMY NYSE Bristol-Myers Squibb Company Fair Value Fair Market Cap 129 B
SNY NASDAQ Sanofi ADR Fair Value Undervalued Market Cap 113.6 B
GSK NYSE GSK plc DRC Fair Value Undervalued Market Cap 101.9 B
TAK NYSE Takeda Pharmaceutical Co Ltd ADR Fair Value Fair Market Cap 69.723 B
TEVA NYSE Teva Pharma Industries Ltd ADR Fair Value Fair Market Cap 48.75 B
HLN NYSE HALEON PLC ADR Fair Value Undervalued Market Cap 40.368 B
RPRX NASDAQ Royalty Pharma Plc Fair Value Fair Market Cap 38.751 B
ZTS NYSE Zoetis Inc Fair Value Undervalued Market Cap 33.93 B
VTRS NASDAQ Viatris Inc Fair Value Fair Market Cap 21.789 B
JAZZ NASDAQ Jazz Pharmaceuticals PLC Fair Value Undervalued Market Cap 14.59 B
RDY NYSE Dr. Reddy’s Laboratories Ltd ADR Fair Value Fair Market Cap 11.996 B
ELAN NYSE Elanco Animal Health Fair Value Overvalued Market Cap 11.831 B
CORT NASDAQ Corcept Therapeutics Incorporated Fair Value Fair Market Cap 7.834 B
AXSM NASDAQ Axsome Therapeutics Inc Fair Value Undervalued Market Cap 6.827 B